[Asthenic disorders correction with Recognan]

Area of Science:

• Neurology
• Geriatrics
• Cardiology

Context:

• Asthenia, or fatigue, is a common symptom impacting physical and cognitive functions, often associated with aging and cardiovascular diseases.
• Senile asthenia syndrome (SAS) reflects age-related decline in physiological reserves and cognitive abilities.
• Asthenic syndrome (AS) is frequently observed in patients with cardiovascular diseases (CVD) and cerebrovascular pathology.

Purpose:

• To evaluate the efficacy of Recognan (citicoline) in managing asthenic syndrome (AS) and improving cognitive functions.
• To assess the impact of Recognan on patients experiencing asthenia related to cardiovascular diseases, senile asthenia syndrome, and post-COVID conditions.

Summary:

• Recognan (citicoline) demonstrates significant effectiveness in alleviating symptoms of asthenia and enhancing cognitive functions.
• Clinical findings indicate that Recognan positively influences asthenic conditions in patients with CVD, SAS, and post-COVID asthenia.
• The study recommends a dosage of 500 mg of Recognan daily for 30 days for its nootropic and antiasthenic effects.

Impact:

• Recognan offers a therapeutic option for improving quality of life in individuals suffering from various forms of asthenia.
• The drug's positive effects on cognitive function suggest potential benefits for age-related cognitive decline and recovery from illness.
• This research supports the use of Recognan as a nootropic and antiasthenic agent in clinical practice.